Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with lynch syndrome

Obstetrics and Gynecology

Volumn 115, Issue 2 SUPPL. 2 PART. 2, 2010, Pages 432-434

  Schmeler, Kathleen M ^a   Daniels, Molly S ^a   Soliman, Pamela T ^a   Broaddus, Russell R ^a   Deavers, Michael T ^a   Vu, Thuy M ^a   Chang, George J ^a   Lu, Karen H ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MSH2;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CASE REPORT; COLORECTAL CARCINOMA; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; HYSTERECTOMY; LAPAROTOMY; MISMATCH REPAIR; PATIENT COUNSELING; PERITONEUM CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; TRANSITIONAL CELL CARCINOMA; URETHRA CARCINOMA;

ADENOSINE TRIPHOSPHATASES; ADULT; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; HUMANS; HYSTERECTOMY; MIDDLE AGED; MUTATION; MUTS HOMOLOG 2 PROTEIN; NEOPLASMS, SECOND PRIMARY; OVARIECTOMY; PERITONEAL NEOPLASMS;

EID: 77649258539     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181b6f4f9     Document Type: Article

References (8)

1. Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Järvinen HJ, et al. The risk of extra-colonic, extra-endome-trial cancer in the Lynch syndrome. Int J Cancer 2008;123: 444-449
2. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81: 214-218
3. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006;296:1507-1517
4. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261-269
5. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-1622
6. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-1615
7. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26:1331-1337
8. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008;135: 419-428